Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $16.14 Average Price Target from Analysts

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) have earned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $16.14.

A number of analysts have recently commented on INZY shares. Stifel Nicolaus began coverage on Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Friday, October 25th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Inozyme Pharma in a research report on Friday, October 25th. Wedbush reiterated an “outperform” rating and issued a $15.00 target price on shares of Inozyme Pharma in a research report on Monday, September 30th. Finally, Jefferies Financial Group restated a “buy” rating and set a $17.00 price target (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th.

Inozyme Pharma Stock Performance

INZY opened at $4.29 on Friday. The firm has a fifty day moving average price of $5.27 and a 200 day moving average price of $4.94. Inozyme Pharma has a 1 year low of $2.71 and a 1 year high of $7.80. The stock has a market cap of $269.13 million, a P/E ratio of -2.94 and a beta of 1.51. The company has a debt-to-equity ratio of 0.48, a current ratio of 9.84 and a quick ratio of 9.84.

Inozyme Pharma (NASDAQ:INZY) last posted its earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Equities research analysts anticipate that Inozyme Pharma will post -1.68 earnings per share for the current year.

Institutional Trading of Inozyme Pharma

Several hedge funds have recently made changes to their positions in INZY. The Manufacturers Life Insurance Company grew its holdings in shares of Inozyme Pharma by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company’s stock valued at $96,000 after purchasing an additional 2,690 shares in the last quarter. American Century Companies Inc. boosted its position in Inozyme Pharma by 11.0% in the 2nd quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock valued at $255,000 after buying an additional 5,673 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in shares of Inozyme Pharma in the second quarter worth $52,000. Rhumbline Advisers increased its position in shares of Inozyme Pharma by 22.0% during the second quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after acquiring an additional 13,867 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Inozyme Pharma by 8.1% during the second quarter. Renaissance Technologies LLC now owns 187,839 shares of the company’s stock worth $838,000 after acquiring an additional 14,139 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.